Evidence map›Paper›PMID 35369315›Full record

ArticleFrontiers in cardiovascular medicine2022

1-Year Outcomes of a Multicenter Randomized Controlled Trial of the Ankura II Thoracic Endoprosthesis for the Endovascular Treatment of Stanford Type B Aortic Dissections.

Chang Shu, Hao He, Weiguo Fu, Wei Guo, Ming Li, Erping Xi, Shuguang Guo, Xueming Chen, Zhanxiang Xiao, Shiqiang Yu and 10 more

Open access · goldAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in cardiovascular medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.3field-weighted citation impact, top 44% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 3 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors at 12 institutions in 1 country.

Chang ShuDepartment of Vascular Surgery, Second Xiangya Hospital, Central South University, Changsha, China.
Hao HeDepartment of Vascular Surgery, Second Xiangya Hospital, Central South University, Changsha, China.
Weiguo FuDepartment of Vascular Surgery, Institute of Vascular Surgery, Zhongshan Hospital, Fudan University, Shanghai, China.
Wei GuoDepartment of Vascular and Endovascular Surgery, Chinese PLA General Hospital, Beijing, China.
Ming LiDepartment of Vascular Surgery, Second Xiangya Hospital, Central South University, Changsha, China.
Erping XiDepartment of Vascular Surgery, Wuhan General Hospital of Guangzhou Military Region, Wuhan, China.
Shuguang GuoDepartment of Vascular Surgery, Kunming General Hospital of Chengdu Military Region, Kunming, China.
Xueming ChenDepartment of Vascular Surgery, Beijing Friendship Hospital, Capital Medical University, Beijing, China.
Zhanxiang XiaoDepartment of Vascular Surgery, Hainan Provincial People's Hospital, Haikou, China.
Shiqiang YuDepartment of Vascular Surgery, The First Affiliated Hospital of the Fourth Military Medical University, Xi'an, China.
Jianhua HuangDepartment of Vascular Surgery, Xiangya Hospital, Central South University, Changsha, China.
Xiangchen DaiDepartment of Vascular Surgery, General Hospital of Tianjin Medical University, Tianjin, China.
Zhiwei WangDepartment of Vascular Surgery, Wuhan University People's Hospital, Wuhan, China.
Wei LiMedical Research and Statistics Center, Fuwai Hospital, Chinese Academy of Medical Sciences, Beijing, China.
Qingshan ZhengDrug Clinical Research Center, Shanghai University of Traditional Chinese Medicine, Shanghai, China.
Quanming LiDepartment of Vascular Surgery, Second Xiangya Hospital, Central South University, Changsha, China.
Lunchang WangDepartment of Vascular Surgery, Second Xiangya Hospital, Central South University, Changsha, China.
Xin LiDepartment of Vascular Surgery, Second Xiangya Hospital, Central South University, Changsha, China.
Junwei WangDepartment of Vascular Surgery, Second Xiangya Hospital, Central South University, Changsha, China.
Feng GuDepartment of Vascular Surgery, Second Xiangya Hospital, Central South University, Changsha, China.
Second Xiangya Hospital of Central South University · CNCentral South University · CNChinese Academy of Medical Sciences & Peking Union Medical College · CNAir Force Medical University · CNCapital Medical University · CNChinese PLA General Hospital · CNKunming General Hospital of Chengdu Military Command · CNShanghai University of Traditional Chinese Medicine · CNTianjin Medical University General Hospital · CNWuhan General Hospital of Guangzhou · CNWuhan University · CNZhongshan Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: The Ankura II Thoracic Stent Graft System (Lifetech, Shenzhen, China) is an evolution of the Ankura stent graft. This study reports one-year outcomes of the Ankura II Thoracic Stent Graft System for endovascular treatment of Stanford type B aortic dissections. Methods: The Ankura II Thoracic Aortic Endovascular Trial was a randomized, single-blinded, clinical trial conducted at 12 Chinese institutes. The enrolled patients diagnosed with Stanford type B aortic dissections (TBADs) were randomly assigned to the Ankura group or Ankura II group. Standard follow-up examinations were performed at 1, 6, and 12 months. Safety and efficacy data were analyzed. Results: 132 patients with TBADs were enrolled. The outcomes for the primary safety end points revealed that the Ankura II stent graft was statistically non-inferior compared to the Ankura stent graft. The 1-month device-related major adverse events (1.6 vs. 0%; Conclusions: The one-year outcomes from this prospective, randomized, multicenter study demonstrate that Ankura II stent graft shows comparable results to Ankura for treating TBADs, resulting in low mortality rates, MAEs and reintervention rates. Clinical Trial Registration: ChiCTR-TRC-12002844.

Indexed as

Ankura IIRCTstent – evolutionthoracic endovascular aortic repairtype B aortic dissection

Identifiers

PMID35369315
PMCPMC8964940
OpenAlexW4220811676

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.